A multicenter, randomized phase III trial comparing osimertinib with durvalumab after concurrent chemoradiotherapy in patients with unresectable, locally advanced non–small cell lung cancer harboring EGFR mutations: JCOG2502 (ODYSSEIA)
A multicenter, randomized phase III trial comparing osimertinib with durvalumab after concurrent chemoradiotherapy in patients with unresectable, locally advanced non–small cell lung cancer harboring EGFR mutations: JCOG2502 (ODYSSEIA). // International Journal of Lung Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S3117504X26000513?dgcid=rss_sd_all
A multicenter, randomized phase III trial comparing osimertinib with durvalumab after concurrent chemoradiotherapy in patients with unresectable, locally advanced non–small cell lung cancer harboring EGFR mutations: JCOG2502 (ODYSSEIA). International Journal of Lung Cancer. https://www.sciencedirect.com/science/article/pii/S3117504X26000513?dgcid=rss_sd_all
“A multicenter, randomized phase III trial comparing osimertinib with durvalumab after concurrent chemoradiotherapy in patients with unresectable, locally advanced non–small cell lung cancer harboring EGFR mutations: JCOG2502 (ODYSSEIA).” International Journal of Lung Cancer.
@article{article89532,
title = {A multicenter, randomized phase III trial comparing osimertinib with durvalumab after concurrent chemoradiotherapy in patients with unresectable, locally advanced non–small cell lung cancer harboring EGFR mutations: JCOG2502 (ODYSSEIA)},
journal = {International Journal of Lung Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S3117504X26000513?dgcid=rss_sd_all}
}